Adamas Announces New Employment Inducement Grant
10 janv. 2020 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020
08 janv. 2020 09h15 HE
|
Adamas Pharmaceuticals, Inc.
-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth...
Adamas Announces Settlement of Patent Litigation with Sandoz Inc.
02 janv. 2020 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment
17 déc. 2019 09h00 HE
|
Adamas Pharmaceuticals, Inc.
- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety...
Adamas Announces New Employment Inducement Grant
09 déc. 2019 16h50 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
21 nov. 2019 16h02 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces New Employment Inducement Grant
08 nov. 2019 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Reports Third Quarter 2019 Financial Results
07 nov. 2019 16h03 HE
|
Adamas Pharmaceuticals, Inc.
- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in...
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
30 oct. 2019 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday,...
Adamas Announces New Employment Inducement Grant
08 oct. 2019 16h03 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new...